Breaking News Instant updates and real-time market news.

DISCA

Discovery

$43.36 /

+1.69 (+4.06%)

06:47
04/07/21
04/07
06:47
04/07/21
06:47

Discovery price target raised to $60 from $35 at Deutsche Bank

Deutsche Bank analyst Bryan Kraft raised the firm's price target on Discovery to $60 from $35 and keeps a Buy rating on the shares. An improved revenue outlook should warrant a higher valuation of the shares, Kraft tells investors in a research note. The analyst now includes "explicit upside potential" for Discovery+ in his forecast.

DISCA Discovery
$43.36 /

+1.69 (+4.06%)

03/26/21
Fly Intel: Top five analyst downgrades
03/26/21 Wells Fargo
Discovery downgraded to Equal Weight from Overweight at Wells Fargo
03/26/21 Wells Fargo
Discovery downgraded to Equal Weight from Overweight at Wells Fargo
03/25/21 MoffettNathanson
Discovery price target raised to $67 from $63 at MoffettNathanson

TODAY'S FREE FLY STORIES

Hot Stocks
Platinum Equity to sell PCI Limited to Celestica for $306M in cash » 21:07
09/21/21
09/21
21:07
09/21/21
21:07
CLS

Celestica

$8.06 /

-0.12 (-1.47%)

Platinum Equity announced…

Platinum Equity announced the signing of a definitive agreement to sell PCI Limited, an electronics manufacturing services provider based in Singapore, to Celestica for $306M in cash. The sale is expected to close in mid-Q4 of 2021, subject to regulatory approval and customary closing conditions.

ShowHide Related Items >><<
CLS Celestica
$8.06 /

-0.12 (-1.47%)

CLS Celestica
$8.06 /

-0.12 (-1.47%)

05/25/21 Stifel
Plexus warning may be signal that supply constraints will worsen, says Stifel
CLS Celestica
$8.06 /

-0.12 (-1.47%)

Earnings
Notable companies reporting before tomorrow's open » 20:25
09/21/21
09/21
20:25
09/21/21
20:25
GIS

General Mills

$58.00 /

-0.745 (-1.27%)

Notable companies…

Notable companies reporting before tomorrow's open, with earnings consensus, include General Mills (GIS), consensus 89c.

ShowHide Related Items >><<
GIS General Mills
$58.00 /

-0.745 (-1.27%)

GIS General Mills
$58.00 /

-0.745 (-1.27%)

09/21/21
Fly Intel: Top five analyst downgrades
09/21/21 Morgan Stanley
General Mills downgraded to Underweight from Equal Weight at Morgan Stanley
09/13/21
Fly Intel: Top five analyst downgrades
09/13/21 Credit Suisse
General Mills downgraded to Neutral from Outperform at Credit Suisse
GIS General Mills
$58.00 /

-0.745 (-1.27%)

GIS General Mills
$58.00 /

-0.745 (-1.27%)

GIS General Mills
$58.00 /

-0.745 (-1.27%)

GIS General Mills
$58.00 /

-0.745 (-1.27%)

Hot Stocks
J2 Global board approves separation into two companies » 19:29
09/21/21
09/21
19:29
09/21/21
19:29
JCOM

J2 Global

$131.44 /

-0.49 (-0.37%)

J2 Global announced that…

J2 Global announced that its board approved its previously announced separation into two independent publicly traded companies - J2 Global, Inc., which will be known as Ziff Davis, Inc. after the separation. The J2 Global Board of Directors declared a special dividend distribution of one share of Consensus common stock for every three shares of J2 Global common stock outstanding as of the close of business on October 1, 2021, the record date for the distribution. The separation is expected to be completed on October 7, 2021. In connection with the separation, J2 Global intends to launch a tender offer to purchase a portion of its outstanding 4.625% senior notes due 2030 at a tender price no greater than 108.00%, with a maximum aggregate purchase price of $330M. J2 Global intends to fund the purchase price in part from a cash distribution by Consensus to J2 Global of $260Mpursuant to the terms of the separation. J2 Global's current CEO, Vivek Shah, will be CEO of Ziff Davis, while Scott Turicchi, J2 Global's current President & CFO, will become CEO of Consensus.

ShowHide Related Items >><<
JCOM J2 Global
$131.44 /

-0.49 (-0.37%)

JCOM J2 Global
$131.44 /

-0.49 (-0.37%)

09/16/21 Spin-Off Research
J2 Global initiated with a Buy at Spin-Off Research
09/10/21 Susquehanna
J2 Global valuation provides little downside risk, says Susquehanna
09/09/21 JPMorgan
Vizio added as new best idea in SMID-cap U.S. Internet at JPMorgan
06/10/21 RBC Capital
J2 Global assumed with an Outperform at RBC Capital
JCOM J2 Global
$131.44 /

-0.49 (-0.37%)

JCOM J2 Global
$131.44 /

-0.49 (-0.37%)

On The Fly
Fly Intel: After-Hours Movers » 18:53
09/21/21
09/21
18:53
09/21/21
18:53
SFIX

Stitch Fix

$35.40 /

-0.995 (-2.73%)

, MRIN

Marin Software

$5.69 /

+0.585 (+11.47%)

, ALPN

Alpine Immune Sciences

$9.82 /

+0.21 (+2.19%)

, LAUR

Laureate Education

$17.18 /

-0.02 (-0.12%)

, BLUE

Bluebird Bio

$17.99 /

+0.06 (+0.33%)

, FDX

FedEx

$252.08 /

+1.26 (+0.50%)

, ADBE

Adobe

$646.30 /

+4.58 (+0.71%)

, SMMT

Summit Therapeutics

$6.46 /

+0.1 (+1.57%)

, LPTX

Leap Therapeutics

$3.41 /

+0.63 (+22.70%)

, GBNH

Greenbrook TMS

$9.43 /

+0.96 (+11.33%)

, XAIR

Beyond Air

$12.55 /

+0.82 (+6.99%)

, INCY

Incyte

$76.03 /

+0.12 (+0.16%)

, H

Hyatt

$73.69 /

-0.87 (-1.17%)

, SAFE

Safehold

$79.51 /

+0.01 (+0.01%)

Check out this evening's…

ShowHide Related Items >><<
XAIR Beyond Air
$12.55 /

+0.82 (+6.99%)

SMMT Summit Therapeutics
$6.46 /

+0.1 (+1.57%)

SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

SAFE Safehold
$79.51 /

+0.01 (+0.01%)

MRIN Marin Software
$5.69 /

+0.585 (+11.47%)

LPTX Leap Therapeutics
$3.41 /

+0.63 (+22.70%)

LAUR Laureate Education
$17.18 /

-0.02 (-0.12%)

INCY Incyte
$76.03 /

+0.12 (+0.16%)

H Hyatt
$73.69 /

-0.87 (-1.17%)

GBNH Greenbrook TMS
$9.43 /

+0.96 (+11.33%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

BLUE Bluebird Bio
$17.99 /

+0.06 (+0.33%)

ALPN Alpine Immune Sciences
$9.82 /

+0.21 (+2.19%)

ADBE Adobe
$646.30 /

+4.58 (+0.71%)

SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

09/15/21 MKM Partners
Stitch Fix price target lowered to $31 from $45 at MKM Partners
06/08/21 Canaccord
Stitch Fix price target raised to $76 from $68 at Canaccord
06/08/21 Truist
Stitch Fix price target raised to $77 from $60 at Truist
06/08/21 MKM Partners
Stitch Fix price target raised to $45 from $29 at MKM Partners
MRIN Marin Software
$5.69 /

+0.585 (+11.47%)

ALPN Alpine Immune Sciences
$9.82 /

+0.21 (+2.19%)

06/30/21 Piper Sandler
Piper reiterates Overweight rating on Alpine following Merck collaboration
12/21/20 H.C. Wainwright
Alpine Immune Sciences initiated with a Buy at H.C. Wainwright
LAUR Laureate Education
$17.18 /

-0.02 (-0.12%)

09/15/21 BMO Capital
Laureate Education resumed with an Outperform at BMO Capital
09/10/21 Morgan Stanley
Laureate Education resumed with an Overweight at Morgan Stanley
BLUE Bluebird Bio
$17.99 /

+0.06 (+0.33%)

08/10/21
Fly Intel: Top five analyst downgrades
08/10/21 BMO Capital
Bluebird Bio price target lowered to $21 from $29 at BMO Capital
08/10/21 Canaccord
Bluebird Bio downgraded to Hold from Buy at Canaccord
08/10/21 Mizuho
Bluebird Bio price target lowered to $29 from $70 at Mizuho
FDX FedEx
$252.08 /

+1.26 (+0.50%)

09/17/21 UBS
FedEx price target lowered to $380 from $397 at UBS
09/17/21 Baird
FedEx sentiment too negative with favorable outlook, says Baird
09/13/21 KeyBanc
FedEx price target lowered to $350 from $370 at KeyBanc
09/13/21 Citi
FedEx price target lowered to $360 from $365 at Citi
ADBE Adobe
$646.30 /

+4.58 (+0.71%)

09/20/21 Wells Fargo
Adobe initiated with an Overweight at Wells Fargo
09/20/21 Citi
Adobe shares may be pricing in front office tailwinds, says Citi
09/17/21 Mizuho
Adobe price target raised to $695 from $640 at Mizuho
09/16/21 BMO Capital
Adobe price target raised to $730 from $630 at BMO Capital
SMMT Summit Therapeutics
$6.46 /

+0.1 (+1.57%)

11/18/20 H.C. Wainwright
Summit Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
LPTX Leap Therapeutics
$3.41 /

+0.63 (+22.70%)

09/19/21 Piper Sandler
Piper Sandler keeps Overweight on Leap Therapeutics, ups target to $5
09/16/21 Piper Sandler
Leap data show 'very favorable early signal,' says Piper Sandler
09/13/21 Raymond James
Leap Therapeutics price target raised to $4 from $3 at Raymond James
09/13/21 Piper Sandler
Leap combo sees 'strong' early response rate, says Piper Sandler
GBNH Greenbrook TMS
$9.43 /

+0.96 (+11.33%)

07/08/21 Desjardins
Greenbrook TMS resumed with a Buy at Desjardins
XAIR Beyond Air
$12.55 /

+0.82 (+6.99%)

04/28/21
Fly Intel: Top five analyst initiations
04/28/21 Truist
Beyond Air initiated with a Buy at Truist
04/28/21 Truist
Beyond Air initiated with a Buy at Truist
INCY Incyte
$76.03 /

+0.12 (+0.16%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
09/01/21 Cowen
Odds of Incyte drug exclusion from class warning 'largely unchanged,' says Cowen
07/20/21 Benchmark
Incyte upgraded to Buy from Hold at Benchmark
H Hyatt
$73.69 /

-0.87 (-1.17%)

08/17/21
Fly Intel: Top five analyst upgrades
08/17/21 Truist
Hyatt upgraded to Hold from Sell at Truist
08/17/21 Truist
Hyatt upgraded to Hold from Sell at Truist
08/16/21 Stifel
Hyatt price target raised to $76.50 from $74 at Stifel
SAFE Safehold
$79.51 /

+0.01 (+0.01%)

09/21/21
Safehold files to sell 2M shares and concurrent private placement
07/30/21 Truist
Safehold price target raised to $80 from $72 at Truist
07/27/21 B. Riley
Safehold price target raised to $110 from $100 at B. Riley
07/22/21 Truist
Truist 'not overly concerned' by Safehold earnings miss
XAIR Beyond Air
$12.55 /

+0.82 (+6.99%)

SMMT Summit Therapeutics
$6.46 /

+0.1 (+1.57%)

SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

SAFE Safehold
$79.51 /

+0.01 (+0.01%)

MRIN Marin Software
$5.69 /

+0.585 (+11.47%)

LPTX Leap Therapeutics
$3.41 /

+0.63 (+22.70%)

LAUR Laureate Education
$17.18 /

-0.02 (-0.12%)

INCY Incyte
$76.03 /

+0.12 (+0.16%)

H Hyatt
$73.69 /

-0.87 (-1.17%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

BLUE Bluebird Bio
$17.99 /

+0.06 (+0.33%)

ALPN Alpine Immune Sciences
$9.82 /

+0.21 (+2.19%)

ADBE Adobe
$646.30 /

+4.58 (+0.71%)

  • 22
    Sep
  • 23
    Sep
  • 22
    Sep
  • 23
    Sep
  • 11
    Nov
SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

INCY Incyte
$76.03 /

+0.12 (+0.16%)

H Hyatt
$73.69 /

-0.87 (-1.17%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

ADBE Adobe
$646.30 /

+4.58 (+0.71%)

XAIR Beyond Air
$12.55 /

+0.82 (+6.99%)

SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

SAFE Safehold
$79.51 /

+0.01 (+0.01%)

MRIN Marin Software
$5.69 /

+0.585 (+11.47%)

LPTX Leap Therapeutics
$3.41 /

+0.63 (+22.70%)

LAUR Laureate Education
$17.18 /

-0.02 (-0.12%)

INCY Incyte
$76.03 /

+0.12 (+0.16%)

H Hyatt
$73.69 /

-0.87 (-1.17%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

BLUE Bluebird Bio
$17.99 /

+0.06 (+0.33%)

ADBE Adobe
$646.30 /

+4.58 (+0.71%)

SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

MRIN Marin Software
$5.69 /

+0.585 (+11.47%)

INCY Incyte
$76.03 /

+0.12 (+0.16%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

ADBE Adobe
$646.30 /

+4.58 (+0.71%)

Hot Stocks
Adobe CEO: We're executing across all growth initiatives » 18:46
09/21/21
09/21
18:46
09/21/21
18:46
ADBE

Adobe

$646.30 /

+4.58 (+0.71%)

In an interview on…

In an interview on CNBC's Mad Money, Shantanu Narayen said, "we feel really good about the quarter, the year and the future." According to Narayen, Adobe's product innovation and vision appeals to larger customers. The company's ability to look around the corner gives clients tremendous confidence, he noted.

ShowHide Related Items >><<
ADBE Adobe
$646.30 /

+4.58 (+0.71%)

ADBE Adobe
$646.30 /

+4.58 (+0.71%)

09/20/21 Wells Fargo
Adobe initiated with an Overweight at Wells Fargo
09/20/21 Citi
Adobe shares may be pricing in front office tailwinds, says Citi
09/17/21 Mizuho
Adobe price target raised to $695 from $640 at Mizuho
09/16/21 BMO Capital
Adobe price target raised to $730 from $630 at BMO Capital
ADBE Adobe
$646.30 /

+4.58 (+0.71%)

ADBE Adobe
$646.30 /

+4.58 (+0.71%)

ADBE Adobe
$646.30 /

+4.58 (+0.71%)

ADBE Adobe
$646.30 /

+4.58 (+0.71%)

Hot Stocks
Four Corners Property Trust acquires Caliber Collision portfolio for $7.2M » 18:26
09/21/21
09/21
18:26
09/21/21
18:26
FCPT

Four Corners Property Trust

$27.23 /

-0.11 (-0.40%)

Four Corners Property…

Four Corners Property Trust announced the acquisition of three Caliber Collision properties for $7.2M. The properties are located in highly trafficked corridors in New York and are corporate-operated under net leases with a weighted average of seven years of term remaining and annual rent increases of 2%. The transaction was priced at a 6.8% cap rate on rent today, exclusive of transaction costs.

ShowHide Related Items >><<
FCPT Four Corners Property Trust
$27.23 /

-0.11 (-0.40%)

FCPT Four Corners Property Trust
$27.23 /

-0.11 (-0.40%)

08/18/21
Fly Intel: Top five analyst downgrades
08/18/21 Raymond James
Four Corners Property Trust downgraded to Outperform from Strong Buy at Raymond James
08/18/21 Raymond James
Four Corners downgraded to Outperform from Strong Buy at Raymond James
12/16/20 Baird
Four Corners Property Trust reinstated with an Outperform at Baird
FCPT Four Corners Property Trust
$27.23 /

-0.11 (-0.40%)

Hot Stocks
Disney says 'Shang-Chi,' 'Jungle Cruise' to stream on Disney+ November 12 » 18:23
09/21/21
09/21
18:23
09/21/21
18:23
DIS

Disney

$171.17 /

-7.47 (-4.18%)

Disney said that, on…

Disney said that, on Friday, November 12, it will host Disney+ Day, a global celebration of its content streaming service. Subscribers to Disney+ will be treated to new content releases across the service's brands, Disney, Pixar, Marvel, Star Wars, National Geographic, and Star in international markets, along with a special presentation on Disney+ for fans with sneak peeks into what's to come. Additionally, the service will continue to engage new audiences around the world, as Disney+ expands into new Asia-Pacific markets on November 12. "In honor of the second anniversary of Disney+, subscribers will have access to promotions and experiences across the Company," the company said. "Disney Parks and Resorts around the world and Disney Cruise Line will roll out the blue carpet for Disney+ fans with some surprise and delight moments including photo opportunities, character moments and more; shopDisney.com will have special offers; popular network shows and syndicated series will join in the celebration along with talent and series across ABC, Disney Channel, ESPN and ESPN+, Freeform, FX, Hulu, National Geographic in the U.S., and on owned channels abroad." The company added that Disney+ Day will feature content premieres from all of its brands, including the streaming premiere of recent films "Shang-Chi and The Legend of The Ten Rings" and "Jungle Cruise," new Disney+ original movie "Home Sweet Home Alone," new shorts from Pixar and Disney Animation studios based on "Frozen" and "Luca," and a new "Simpsons" short. In addition, in honor of Disney+ Day, Disney+ will make its debut in South Korea and Taiwan on November 12, and in Hong Kong on November 16. Reference Link

ShowHide Related Items >><<
DIS Disney
$171.17 /

-7.47 (-4.18%)

DIS Disney
$171.17 /

-7.47 (-4.18%)

09/21/21 KeyBanc
Disney+ subscriber guidance 'a very modest incremental negative,' says KeyBanc
09/21/21 Daiwa
Disney initiated with a Buy at Daiwa
09/13/21 Stephens
Recent Apple TV+ news positive for Roku, says Stephens
09/10/21 Truist
Apple will likely appeal ruling in Epic case, says Truist
DIS Disney
$171.17 /

-7.47 (-4.18%)

DIS Disney
$171.17 /

-7.47 (-4.18%)

DIS Disney
$171.17 /

-7.47 (-4.18%)

DIS Disney
$171.17 /

-7.47 (-4.18%)

Periodicals
McDonald's to significantly cut use of plastic in toys by 2025, Reuters reports » 18:22
09/21/21
09/21
18:22
09/21/21
18:22
MCD

McDonald's

$240.58 /

+1.56 (+0.65%)

McDonald's announced…

McDonald's announced it will significantly cut the use of plastic in the more than 1 billion children's toys it sells globally each year by the end of 2025, Reuters' Hilary Russ reports. For example, the change involves swapping out a plastic figurine of Batman for one made with a dozen cardboard pieces that kids can assemble themselves. More toys will also be made from recycled or plant-based plastics, McDonald's said. The changes will allow the company to reduce its use of virgin fossil fuel-based plastic for Happy Meals by 90% compared with 2018. Reference Link

ShowHide Related Items >><<
MCD McDonald's
$240.58 /

+1.56 (+0.65%)

MCD McDonald's
$240.58 /

+1.56 (+0.65%)

07/29/21 RBC Capital
McDonald's price target raised to $268 from $263 at RBC Capital
07/29/21 Truist
McDonald's price target raised to $266 from $255 at Truist
07/29/21 Wedbush
McDonald's price target raised to $270 from $265 at Wedbush
07/29/21 Stephens
McDonald's price target raised to $260 from $245 at Stephens
MCD McDonald's
$240.58 /

+1.56 (+0.65%)

MCD McDonald's
$240.58 /

+1.56 (+0.65%)

MCD McDonald's
$240.58 /

+1.56 (+0.65%)

MCD McDonald's
$240.58 /

+1.56 (+0.65%)

Hot Stocks
Rhythm granted authorization to market IMCIVREE in Great Britain » 18:17
09/21/21
09/21
18:17
09/21/21
18:17
RYTM

Rhythm Pharmaceuticals

$12.57 /

-0.04 (-0.32%)

Rhythm Pharmaceuticals…

Rhythm Pharmaceuticals announced that Great Britain's Medicines & Healthcare Products Regulatory Agency, or MHRA, has granted marketing authorisation to IMCIVREE, or setmelanotide, for the treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin, or POMC, including proprotein convertase subtilisin/kexin type 1, or PCSK1, deficiency or biallelic leptin receptor, or LEPR, deficiency in adults and children 6 years of age and above. IMCIVREE was selected for evaluation as a "Highly Specialised Technology" by the National Institute for Health and Care Excellence, or NICE. NICE is scheduled to review the dossier for IMCIVREE in December 2021. Guidance for coverage of IMCIVREE under the U.K's National Health Service, or NHS, is anticipated in the second quarter of 2022.

ShowHide Related Items >><<
RYTM Rhythm Pharmaceuticals
$12.57 /

-0.04 (-0.32%)

RYTM Rhythm Pharmaceuticals
$12.57 /

-0.04 (-0.32%)

09/14/21 Goldman Sachs
Rhythm Pharmaceuticals assumed with Neutral from Sell at Goldman Sachs
08/04/21
Fly Intel: Top five analyst downgrades
08/04/21 Ladenburg
Rhythm Pharmaceuticals downgraded to Neutral from Buy at Ladenburg
08/04/21 BofA
Rhythm Pharmaceuticals downgraded to Underperform from Neutral at BofA
RYTM Rhythm Pharmaceuticals
$12.57 /

-0.04 (-0.32%)

  • 05
    Feb
RYTM Rhythm Pharmaceuticals
$12.57 /

-0.04 (-0.32%)

Periodicals
Lululemon says Mirror CEO stepping down, CNBC reports » 18:17
09/21/21
09/21
18:17
09/21/21
18:17
LULU

Lululemon

$424.32 /

+4.35 (+1.04%)

Lululemon will begin the…

Lululemon will begin the search for a new CEO of its Mirror business after its founder Brynn Putnam decided to step down, CNBC's Lauren Thomas reports, citing a memo to employees. The report states that the change is effective immediately, though Putnam will continue to serve as an advisor to Mirror until next July. Reference Link

ShowHide Related Items >><<
LULU Lululemon
$424.32 /

+4.35 (+1.04%)

LULU Lululemon
$424.32 /

+4.35 (+1.04%)

09/17/21 Oppenheimer
Lululemon price target raised to $520 from $405 at Oppenheimer
09/10/21 Argus
Lululemon price target raised to $500 from $416 at Argus
09/10/21 UBS
Lululemon price target raised to $430 from $375 at UBS
09/09/21 Guggenheim
Lululemon price target raised to $475 from $450 at Guggenheim
LULU Lululemon
$424.32 /

+4.35 (+1.04%)

LULU Lululemon
$424.32 /

+4.35 (+1.04%)

LULU Lululemon
$424.32 /

+4.35 (+1.04%)

LULU Lululemon
$424.32 /

+4.35 (+1.04%)

Hot Stocks
CF Industries to restart ammonia plant at its Billingham complex » 18:12
09/21/21
09/21
18:12
09/21/21
18:12
CF

CF Industries

$48.99 /

+0.98 (+2.04%)

CF Industries Holdings…

CF Industries Holdings announced that it is immediately restarting the ammonia plant at its Billingham, UK, complex. The restart follows an interim agreement reached today to cover the costs to restart the ammonia plant and produce CO2 for the UK market. CO2 is a byproduct of the ammonia production process. Safely restarting the ammonia plant at the Billingham Complex is expected to take several days.

ShowHide Related Items >><<
CF CF Industries
$48.99 /

+0.98 (+2.04%)

CF CF Industries
$48.99 /

+0.98 (+2.04%)

08/20/21
Fly Intel: Top five analyst upgrades
08/20/21 HSBC
CF Industries upgraded to Buy from Hold at HSBC
08/17/21 Berenberg
CF Industries upgraded to Buy from Hold at Berenberg
07/08/21 RBC Capital
CF Industries price target raised to $57 from $52 at RBC Capital
CF CF Industries
$48.99 /

+0.98 (+2.04%)

CF CF Industries
$48.99 /

+0.98 (+2.04%)

CF CF Industries
$48.99 /

+0.98 (+2.04%)

Hot Stocks
Bristol-Myers' Celgene receives FDA orphan designation for luspatercept » 18:11
09/21/21
09/21
18:11
09/21/21
18:11
BMY

Bristol-Myers

$60.31 /

-0.19 (-0.31%)

According to a post on…

According to a post on the FDA's website, Celgene's treatment of Alpha-thalassemia, luspatercept, received orphan designation. Reference Link

ShowHide Related Items >><<
BMY Bristol-Myers
$60.31 /

-0.19 (-0.31%)

BMY Bristol-Myers
$60.31 /

-0.19 (-0.31%)

09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/27/21 Mizuho
Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho
07/26/21 Truist
Bristol-Myers assumed with a Buy at Truist
BMY Bristol-Myers
$60.31 /

-0.19 (-0.31%)

BMY Bristol-Myers
$60.31 /

-0.19 (-0.31%)

BMY Bristol-Myers
$60.31 /

-0.19 (-0.31%)

BMY Bristol-Myers
$60.31 /

-0.19 (-0.31%)

Earnings
Oil-Dri awarded patent in Indonesia for mineral-based formulation » 18:09
09/21/21
09/21
18:09
09/21/21
18:09
ODC

Oil-Dri Corporation of America

$34.65 /

+0.11 (+0.32%)

Oil-Dri announces that…

Oil-Dri announces that the Indonesian Directorate General of Intellectual Property has issued Patent IDP-000071991, titled "Clay Product and Uses Thereof." The patent protects the novel, mineral-based formulation used in Amlan's existing natural feed additives, Varium for poultry and NeoPrime for swine, that provides animal protein producers with natural solutions to maintain intestinal health and optimize production efficiency. The products are sold and marketed in international markets by Amlan International, the animal health business of Oil-Dri, trading in Indonesia as PT Amlan Perdagangan Internasional.

ShowHide Related Items >><<
ODC Oil-Dri Corporation of America
$34.65 /

+0.11 (+0.32%)

Hot Stocks
Genzyme receives FDA orphan designation for anti-thymocyte globulin » 18:08
09/21/21
09/21
18:08
09/21/21
18:08
SNY

Sanofi

$48.24 /

+0.345 (+0.72%)

According to a post on…

According to a post on the FDA's website, Genzyme's anti-thymocyte globulin received orphan designation. Reference Link

ShowHide Related Items >><<
SNY Sanofi
$48.24 /

+0.345 (+0.72%)

SNY Sanofi
$48.24 /

+0.345 (+0.72%)

09/20/21 Oppenheimer
Denali Therapeutics initiated with an Outperform at Oppenheimer
09/20/21 Citi
Citi says 'remain upbeat' on Pfizer Covid revenue despite mixed panel vote
09/14/21 Mizuho
Kadmon downgraded to Neutral from Buy at Mizuho
09/10/21 UBS
Kadmon downgraded to Neutral from Buy at UBS
SNY Sanofi
$48.24 /

+0.345 (+0.72%)

SNY Sanofi
$48.24 /

+0.345 (+0.72%)

SNY Sanofi
$48.24 /

+0.345 (+0.72%)

Hot Stocks
FedEx says anticipate similar level of headwinds in Q2 as experienced in Q1 » 18:05
09/21/21
09/21
18:05
09/21/21
18:05
FDX

FedEx

$252.08 /

+1.26 (+0.50%)

Says impact to operations…

Says impact to operations from labor shortages to persist through the rest of 2021. Says Q2 headwinds also driven by expansion of ground business, higher health care expenses, COVID-related air network inefficiencies, and reduced aviation excise taxes.

ShowHide Related Items >><<
FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

09/17/21 UBS
FedEx price target lowered to $380 from $397 at UBS
09/17/21 Baird
FedEx sentiment too negative with favorable outlook, says Baird
09/13/21 KeyBanc
FedEx price target lowered to $350 from $370 at KeyBanc
09/13/21 Citi
FedEx price target lowered to $360 from $365 at Citi
FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

Hot Stocks
Glaukos announces FDA orphan designation for treatment of corneal ulcers » 18:04
09/21/21
09/21
18:04
09/21/21
18:04
GKOS

Glaukos

$50.92 /

-0.93 (-1.79%)

According to a post on…

According to a post on the FDA's website, Glaukos' treatment of corneal ulcers, riboflavin 5'-phosphate sodium, received orphan designation. Reference Link

ShowHide Related Items >><<
GKOS Glaukos
$50.92 /

-0.93 (-1.79%)

GKOS Glaukos
$50.92 /

-0.93 (-1.79%)

09/15/21 Piper Sandler
Piper says Glaukos patent settlement doesn't ease reimbursement challenges
09/01/21 William Blair
CMS panel sides with Glaukos on all proposals, says William Blair
08/06/21 Piper Sandler
Glaukos price target lowered to $45 from $80 at Piper Sandler
07/28/21 Citi
Glaukos price target lowered to $52 from $94 at Citi
GKOS Glaukos
$50.92 /

-0.93 (-1.79%)

GKOS Glaukos
$50.92 /

-0.93 (-1.79%)

Hot Stocks
Allison Transmission and Jing-Jin Electric sign global partnership agreement » 18:02
09/21/21
09/21
18:02
09/21/21
18:02
ALSN

Allison Transmission

$35.25 /

-0.03 (-0.09%)

Allison Transmission and…

Allison Transmission and Jing-Jin Electric, a Chinese electrified propulsion leader in components, assemblies and systems for global automotive and commercial vehicle customers, have signed a broad, global strategic collaboration partnership agreement to accelerate the development of industry-leading electrified powertrain solutions for global commercial vehicles. The companies will leverage JJE's leadership in electric motor and inverter development and its strong presence in the Chinese commercial vehicle electrified powertrain market, while harnessing Allison's deep experience and investments in fully electric and electric hybrid commercial duty propulsion systems, commercial vehicle duty cycle expertise, global OEM relationships, and a worldwide distributors and dealers channel. The combined capabilities will enable the strategic collaboration partnership to offer innovative and reliable electrified propulsion solutions, to commercial vehicle manufacturers around the world.

ShowHide Related Items >><<
ALSN Allison Transmission
$35.25 /

-0.03 (-0.09%)

ALSN Allison Transmission
$35.25 /

-0.03 (-0.09%)

07/13/21 JPMorgan
JPMorgan sees opportunities in machinery, upgrades three to Overweight
06/01/21
Fly Intel: Top five analyst downgrades
05/31/21 Goldman Sachs
Allison Transmission downgraded to Sell from Buy at Goldman Sachs
04/21/21 Raymond James
Allison Transmission downgraded to Market Perform from Strong Buy at Raymond James
ALSN Allison Transmission
$35.25 /

-0.03 (-0.09%)

Hot Stocks
FedEx says U.S. parcel market will grow to 101M packages per day by 2022 » 18:02
09/21/21
09/21
18:02
09/21/21
18:02
FDX

FedEx

$252.08 /

+1.26 (+0.50%)

Says market projections…

Says market projections are slightly lower than last quarter as e-commerce percentage as percentage of retail has declined. Says forecasting 10% annual growth rate of U.S. domestic market volumes through 2026.

ShowHide Related Items >><<
FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

09/17/21 UBS
FedEx price target lowered to $380 from $397 at UBS
09/17/21 Baird
FedEx sentiment too negative with favorable outlook, says Baird
09/13/21 KeyBanc
FedEx price target lowered to $350 from $370 at KeyBanc
09/13/21 Citi
FedEx price target lowered to $360 from $365 at Citi
FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

Periodicals
Blizzard's executive producer of Overwatch, to leave, Bloomberg says » 18:00
09/21/21
09/21
18:00
09/21/21
18:00
ATVI

Activision Blizzard

$73.06 /

-3.19 (-4.18%)

Blizzard…

Blizzard Entertainment's senior ranks will grow thinner as Chacko Sonny, executive producer of Overwatch, informed his colleagues that this coming Friday will be his last day, wrote Bloomberg's Jason Schreier. According to the Bloomberg story, Sonny didn't say why he was leaving, nor did he refer to the current "turmoil related to the lawsuit or the SEC probe." Reference Link

ShowHide Related Items >><<
ATVI Activision Blizzard
$73.06 /

-3.19 (-4.18%)

ATVI Activision Blizzard
$73.06 /

-3.19 (-4.18%)

09/15/21 KeyBanc
EA's delay of Battlefield 2042 slight positive for Activision, says KeyBanc
09/15/21 Benchmark
EA shares reacting negatively to Battlefield 2042 delay rumors, says Benchmark
09/15/21 Truist
Battlefield 2042 delay would be 'modest negative' for EA, says Truist
09/13/21 JPMorgan
Activision should be bought on China regulation concerns, says JPMorgan
ATVI Activision Blizzard
$73.06 /

-3.19 (-4.18%)

ATVI Activision Blizzard
$73.06 /

-3.19 (-4.18%)

ATVI Activision Blizzard
$73.06 /

-3.19 (-4.18%)

ATVI Activision Blizzard
$73.06 /

-3.19 (-4.18%)

Hot Stocks
FedEx says labor markets are biggest issue, driver of lower than expected result » 17:55
09/21/21
09/21
17:55
09/21/21
17:55
FDX

FedEx

$252.08 /

+1.26 (+0.50%)

COO Rajesh Subramaniam…

COO Rajesh Subramaniam says in FedEx Groupd, over 600K packages per day are being rerouted. Says in the early stages of unlocking value from digital innovation, confident this will play significant part of FedEx success. Comments taken from Q1 earnings conference call.

ShowHide Related Items >><<
FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

09/17/21 UBS
FedEx price target lowered to $380 from $397 at UBS
09/17/21 Baird
FedEx sentiment too negative with favorable outlook, says Baird
09/13/21 KeyBanc
FedEx price target lowered to $350 from $370 at KeyBanc
09/13/21 Citi
FedEx price target lowered to $360 from $365 at Citi
FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

FDX FedEx
$252.08 /

+1.26 (+0.50%)

Conference/Events
Morgan Stanley Australia health analysts hold analyst/industry conference call » 17:40
09/21/21
09/21
17:40
09/21/21
17:40

Australia Healthcare…

Australia Healthcare Analysts Laaman and Kirby-Lewis, along with Keith Berman, Biomedical Reimbursement & Business Development Consultant discuss Australia's Healthcare Industry on an Analyst/Industry conference call to be held on September 21 at 6 pm.

Conference/Events
GoodRx to hold an educational webinar » 17:29
09/21/21
09/21
17:29
09/21/21
17:29
GDRX

GoodRx

$46.30 /

+0.3 (+0.65%)

Management holds a…

Management holds a webinar entitled, "101 Educational Webinar" on September 30 at 2:30 pm. Webcast Link

ShowHide Related Items >><<
GDRX GoodRx
$46.30 /

+0.3 (+0.65%)

GDRX GoodRx
$46.30 /

+0.3 (+0.65%)

09/14/21 Credit Suisse
GoodRx price target raised to $52 from $45 at Credit Suisse
08/31/21 Barclays
GoodRx upgraded to Overweight from Equal Weight at Barclays
08/13/21 Raymond James
GoodRx upgraded to Outperform from Market Perform at Raymond James
08/13/21 Raymond James
GoodRx upgraded to Outperform from Market Perform at Raymond James
GDRX GoodRx
$46.30 /

+0.3 (+0.65%)

  • 23
    Sep
GDRX GoodRx
$46.30 /

+0.3 (+0.65%)

GDRX GoodRx
$46.30 /

+0.3 (+0.65%)

GDRX GoodRx
$46.30 /

+0.3 (+0.65%)

Hot Stocks
Stitch Fix says opened up Freestyle to new-to-Stitch Fix customers » 17:29
09/21/21
09/21
17:29
09/21/21
17:29
SFIX

Stitch Fix

$35.40 /

-0.995 (-2.73%)

Says doubled UK business.…

Says doubled UK business. Says leveraging algorithmically generated offerings. Says significant runway for growth ahead. Says plans to test curated search in 2022. Says plans to scale to 200 branded shops across women's and men's categories. Says opened up Freestyle to new-to-Stitch Fix customers. Comments taken from Q4 earnings conference call.

ShowHide Related Items >><<
SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

09/15/21 MKM Partners
Stitch Fix price target lowered to $31 from $45 at MKM Partners
06/08/21 Canaccord
Stitch Fix price target raised to $76 from $68 at Canaccord
06/08/21 Truist
Stitch Fix price target raised to $77 from $60 at Truist
06/08/21 MKM Partners
Stitch Fix price target raised to $45 from $29 at MKM Partners
SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

SFIX Stitch Fix
$35.40 /

-0.995 (-2.73%)

Earnings
BioDelivery Sciences sees Q3 revenue $38M-$42M, consensus $44.07M » 17:25
09/21/21
09/21
17:25
09/21/21
17:25
BDSI

BioDelivery Sciences

$4.02 /

+0.12 (+3.08%)

BioDelivery Sciences said…

BioDelivery Sciences said in a regulatory filing that while the company continues to evaluate the longer term impact on its business of Alvogen's conduct, as alleged in the Motion, the company currently believes that net revenues for the quarter ended September 30, 2021 will be in a range of $38 million to $42 million. The Company remains confident in the validity of its Orange Book patents listed for BELBUCA and will continue to vigorously defend its patent rights.

ShowHide Related Items >><<
BDSI BioDelivery Sciences
$4.02 /

+0.12 (+3.08%)

BDSI BioDelivery Sciences
$4.02 /

+0.12 (+3.08%)

05/06/21 Roth Capital
BioDelivery Sciences price target lowered to $6.25 from $7 at Roth Capital
03/11/21 H.C. Wainwright
BioDelivery Sciences price target lowered to $5.50 from $7 at H.C. Wainwright
BDSI BioDelivery Sciences
$4.02 /

+0.12 (+3.08%)

Hot Stocks
Incyte trading resumes  17:25
09/21/21
09/21
17:25
09/21/21
17:25
INCY

Incyte

$76.03 /

+0.12 (+0.16%)

 
ShowHide Related Items >><<
INCY Incyte
$76.03 /

+0.12 (+0.16%)

INCY Incyte
$76.03 /

+0.12 (+0.16%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
09/09/21 Benchmark
Sanofi deal for Kadmon reinforces Incyte thesis, says Benchmark
09/01/21 Cowen
Odds of Incyte drug exclusion from class warning 'largely unchanged,' says Cowen
07/20/21 Benchmark
Incyte upgraded to Buy from Hold at Benchmark
INCY Incyte
$76.03 /

+0.12 (+0.16%)

INCY Incyte
$76.03 /

+0.12 (+0.16%)

INCY Incyte
$76.03 /

+0.12 (+0.16%)

INCY Incyte
$76.03 /

+0.12 (+0.16%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.